deltatrials
Completed PHASE2 NCT00003007

Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma

Interferon Maintenance in Advanced Multiple Myeloma After Using High-Dose Melphalan as Myeloablative Chemotherapy: A Pilot Study

Sponsor: University of Tennessee

Conditions Multiple Myeloma and Plasma Cell Neoplasm
Interventions cyclophosphamide dexamethasone melphalan peripheral blood stem cell transplantation recombinant interferon alfa sargramostim
Updated 5 times since 2017 Last updated: Jun 25, 2013 Started: Jul 31, 1996 Completion: Jan 31, 2004

A PHASE2 clinical study on Multiple Myeloma and Plasma Cell Neoplasm, this trial is completed. The trial is conducted by University of Tennessee and has accumulated 5 data snapshots since 1996. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Jul 1996

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University of Tennessee
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Memphis, United States